We thus reasoned that an unbiased, mass spectrometry (MS)-based proteomics analysis of cerebrospinal fluid (CSF) from heathy controls, PD individuals with and without LRRK2 G2019S mutation and non-manifesting LRRK2 G2019S carriers could uncover much-needed biomarkers. The gene discussed is LRRK2; the disease is Parkinson disease.